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ABSTRACT 
Context: The hand-held fan is an inexpensive and safe way to provide facial airflow which 
may reduce the sensation of chronic refractory breathlessness, a frequently encountered 
symptom. 
Objectives: To test the feasibility of developing an adequately powered, multi-centre, multi-
national randomized controlled trial (RCT) comparing the efficacy of a hand-held fan and 
exercise advice with advice alone in increasing activity in people with chronic refractory 
breathlessness due to a variety of medical conditions measuring: recruitment rates; data 
quality; and potential primary outcome measures. 
Methods: A phase II, multi-site, international, parallel, non-blinded, mixed-methods RCT. 
Participants were centrally randomized to fan or control. All received breathlessness self-
management/exercise advice, and were followed-up weekly for four weeks. 
Participants/carers were invited to participate in a semi-structured interview at the study’s 
conclusion. 
Results: 97 people were screened, 49 randomized (mean age 68; 49% men) and 43 
completed the study. Site recruitment varied from 0.25 to 3.3/month and 
screening:randomization from 1.1:1 to 8.5:1. There were few missing data except for the 
Chronic Obstructive Pulmonary Disease Self-efficacy Scale (two thirds of data missing). No 
harms were observed. Three interview themes included a: i) fan is a helpful self-management 
strategy; ii) fan aids recovery; and iii) symptom control trial was welcome.   
Conclusion: A definitive, multi-site trial to study the use of the hand-held fan as part of self-
management of chronic refractory breathlessness is feasible. Participants found the fan 
useful. However, the value of information for changing practice or policy is unlikely to 
justify the expense of such a trial, given perceived benefits, the minimal costs and an absence 
of harms demonstrated in this study. 
Trial Registration:  
Australian and New Zealand Clinical Trials Registry (ACTRN12614000525684). 
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INTRODUCTION 
Breathlessness is a devastating symptom prevalent in many progressive chronic illnesses. It 
affects most people with lung cancer(1) and chronic obstructive pulmonary disease (COPD) 
(2) and heart failure.(3) It is a frightening and disabling symptom for both patient and carer, 
and is associated with poorer survival,(4) unscheduled hospital attendance(5) and 
admission.(6;7) Despite advances in managing breathlessness,(8;9) many patients experience 
chronic refractory breathlessness, often worsening as death approaches.(10) The multi-
faceted nature of breathlessness means any incremental improvements in its management is 
likely to benefit patients’ wellbeing and their physical function, whilst helping to minimize 
carers’ distress.(11) 
Such patients often experience breathlessness precipitated or exacerbated by exertion or 
anxiety. A smaller sub-group may experience episodic, unheralded breathlessness for which 
no precipitating cause can be identified.(12;13) Non-pharmacological and pharmacological 
interventions are the mainstay of breathlessness management.(14) Self-efficacy assists 
patients manage difficult symptoms more effectively, improving quality of life.(15) 
Pharmacological treatments for breathlessness, such as regular, low dose, sustained release 
morphine provides some relief (16-18) but may have adverse effects and may not be suitable 
nor acceptable for some people.  Exercise may reduce the impact of breathlessness in some 
people through increasing self-efficacy and fitness.(19;20)  Despite benefits associated with 
exercise, exercise-induced breathlessness often limits physical activity because it is 
unpleasant or because patients believe it may be harmful,(19) further reducing their capacity 
to cope with being breathless. Supporting continued physical activity is a key strategy for 
minimising chronic refractory breathlessness.  
There is emerging evidence that facial airflow can reduce the sensation of breathlessness.(21) 
In studies evaluating a UK Breathlessness Intervention Service (BIS) (22-24) patients and 
carers consistently cited the fan as an important intervention. A randomized controlled trial 
(RCT), crossover study of “fan to face” versus “fan to leg” in patients with breathlessness at 
rest due to any aetiology, demonstrated relief.(25) Another phase II, parallel group trial of 
“fan to face” versus acupressure wristband in people with advanced cancer/COPD 
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demonstrated that 50% were still using the fan at two months compared with only 20% using 
the wristband.(26) A recent RCT of medical air versus oxygen showed equal benefit from 
both,(27) with the authors concluding that the effective agent may have been the simple 
passage of air.   
This phase II study explored the feasibility of conducting an adequately powered, multi-
centre, multi-national randomized controlled trial comparing the efficacy of a hand held fan 
and exercise advice with exercise advice alone in increasing activity levels in people with 
optimally treated aetiologies of breathlessness from any cause to evaluate:  
i) Is recruitment possible in terms of number and rate? 
ii) What are the data quality and utility of the proposed outcome measures? 
iii) What is the best primary outcome measure for any subsequent phase III study? 
iv) Is there any signal of a dose response?   
 
 
METHODS 
Study Design: This was a phase II, multi-site, international, parallel arm, non-blinded, 
feasibility RCT with a qualitative sub-study. Participants were allocated to an intervention or 
control arm according to a block randomisation schedule generated by a central registry using 
a 1:1:2 ratio: low flow rate (Fan A); high flow rate (Fan B); No Fan. Each site had access to 
sequentially numbered, opaque, sealed envelopes with the allocation concealed from the 
investigating team. All groups received standardized advice regarding breathlessness self-
management exercises. Participants were followed-up weekly for four weeks.  
Participants and their carers’ were invited to participate in a semi-structured interview as they 
finished the study, purposively sampled to include all groups, and by aetiology of 
breathlessness. A topic guide, developed from the literature and expertise of the research 
team was used to:  
A) explore the experience of using the fan (or not) and its impacts on activities, wellbeing 
and self-efficacy; and  
B) understand the experience of study participation.  
Interviews were conducted at the participants’ homes, or clinical setting of choice.  
Participants and setting:  
© 2017. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/
5 
Eligible participants provided written informed consent and were community dwelling adults 
with refractory breathlessness due to a variety of medical conditions scoring 3 or higher on 
the modified Medical Research Council (mMRC) dyspnoea scale.(28) Those who had used a 
hand held fan within the previous week, had a documented cognitive impairment or were too 
unwell were excluded. All participants were informed that the trial intervention was the fan, 
and if allocated to the control arm, a fan would be provided at study completion. 
Participants were identified from cardio-respiratory, oncology and palliative care outpatient 
clinics and day hospices at two UK services and two Australian sites. 
Interventions: In addition to verbal advice, participants received an information leaflet which 
contained some breathing control exercises, positions for recovery from breathlessness, 
advice about the importance of exercise, some simple exercises to try and, for those 
randomized to the fan, instructions on its use. With permission, the leaflets were adapted 
from the Cambridge Breathlessness Intervention Service (BIS).(29) 
Study outcomes:  
i) Recruitment rate, screening/randomisation ratio, attrition rate; 
ii) Proportion/pattern of missing data in the proposed phase III outcome measures: 
a. Activity: i) ActivPAL™ monitor average step count,(30) ii) six minute walk test 
[6MWT],(31) iii) Lifespace Mobility Assessment(32); iv) Australian-modified 
Karnofsky Performance Status [AKPS];(33)  
b. Self-efficacy: i) General Self Efficacy Scale(34) [patient and carer], ii) COPD 
Self-efficacy Scale;(35) 
c. Breathlessness assessment: i) intensity and unpleasantness using 0-10 numerical 
rating scale [NRS];(36;37) iii) fan use questionnaire; 
d. Health service use;  
iii) Carer burden (Zarit -6).(38) Variance of candidate primary outcome measures; 
qualitative interview responses. 
iv) Any evidence of a dose/ response relationship.  
All study measures were assessed at baseline (Day -8 to 0) and at 4 weeks (Day 28).  
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Sample size: It was considered that at least 30 participants should be sufficient to address the 
stated feasibility questions, and inform the sample size for a phase III trial given that fully 
powered studies on clinical interventions in breathlessness only have total recruitment of 
between 100 and 300 to have clinically meaningful results.(39)  
Statistical methods:  
The quantitative data were analysed using the STATA V13.0 statistical software. The 
primary focus of the analyses was on data collected on Day 28 after randomisation. As a 
feasibility study, data were analysed descriptively. For the potential phase III outcomes, the 
intervention group was classified as “fan” and “no fan” irrespective of flow rate and 
independent sample t-tests or chi-squared tests were applied. Comparisons between groups 
on the changes between baseline and Day28 of main study outcomes were also conducted 
using non-parametric approach (Mann-Whitney U test) given that results were not normally 
distributed and not independent. A type I error rate of 5% was adopted for all hypothesis 
testing. As a pilot study, no data were imputed. The quantitative data are reported according 
to the Consolidated Standards of Reporting Trials (CONSORT) guidelines.  
The qualitative data were analyzed using a thematic framework (40) and reported according 
to the consolidated criteria for reporting qualitative research (COREQ)guidelines(41) 
ensuring attention to: clarification and justification; procedural rigor; representativeness; 
interpretive rigour; reflexivity and evaluation rigor; and transferability. Codes generated from 
the data allowed emerging themes to be identified. Typical quotes were selected and their 
context preserved.  
Ethics:  
Human Research Ethics approvals and institutional permissions were obtained. The trial was 
registered before the first person was enrolled. (Australian and New Zealand Clinical Trials 
Registry (ACTRN12614000525684) 
 
RESULTS 
This study recruited between February 2013 and April 2014.   
Recruitment feasibility: Of 97 screened participants, 49 were randomized and 43 completed 
the trial. (Figure 1) Recruitment per site varied from 0.25/month to 3.3/month and the 
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screening to randomisation from 1.1:1 to 8.5:1. Only 6 participants withdrew, all due to 
deterioration in health, all of whom were in the control arm. 
Only 10 caregivers were recruited, and only seven completed the study. In view of this small 
number the data from the GSES and Zarit 6 are not presented here, although they are 
available on request. 
[Insert Figure 1- Consort Figure] 
Participant characteristics: Baseline demographic and clinical characteristics were well-
balanced between the treatment and control groups (Table 1).  The average age of 
participants was 68 years with equal numbers of men (49%) and women (51%) recruited. 
Approximately two-thirds had an AKPS score of 70 or above indicating an ability to self-care 
but not work). The mean AKPS for participants who withdrew was 64.3 (SD + 9.8). On 
average, participants had moderate intensity of breathlessness which restricted walking on the 
level ground to 100yds. 
[Insert Table 1 here]  
 
Volume and patterns of missing data: Missing data for each potential phase III outcome 
variable are summarized. Data were missing as follows: two data points (5%) on the average 
steps per day (1 in each arm); two data points (5%) on the General Self-Efficacy (all in the 
control arm), and five data points (12%) on 6 Minute Walk test (four in the treatment and one 
in the control arms). However there was a significant amount of missing data in the COPD 
Self-efficacy scale with 16 (67%) and 13 (68%) data points missing for the treatment and 
control arms respectively. Study nurses reported that participants found completing the 
COPD Self-efficacy Scale to be repetitive and less relevant than the General Self Efficacy 
Score. 
Outcomes: Table 2 shows the potential Phase III outcome variable measures for both groups 
at week four, and the comparisons of the differences (week 4 minus baseline) for the 
outcomes between the treatment and control groups. The sample size did not allow 
exploration of a fan / dose response. None of the outcome variables yielded a significant 
difference between groups.   
[Insert Table 2 here] 
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Harms: No harms or unintended effects were observed in either the intervention or control 
groups.   
Outcomes were also informed by the semi-structured interviews, summarized in the 
following section. 
Semi-structured interviews 
A purposive sample of 12 trial participants participated in the semi-structured interview. 
While all trial participants were invited to have a consenting family carer join the interview, 
only one patient-dyad interview was undertaken. . Interview recruitment occurred until no 
new qualitative information was generated. Seven interview participants were from the fan 
arm and five from the control. 
Findings 
Three main themes were expressed: two regarding the fan: i) the fan as a helpful self-
management strategy; ii) the fan helps reduce recovery time; and one regarding the trial iii) a 
positive experience.   
i) The fan as a helpful self-management strategy  
There was a strong perception that integrating the fan into daily activities had helped self-
management and control of breathlessness, with improved confidence about exertion. The fan 
could be tailored to particular situations. Some participants found the fan helpful to use 
before, during and as part of their recovery from exertion. Others used the fan in place of “as 
needed” beta-agonist metered dose inhalers (MDIs) (Textbox 1).  
While participants used the fan in a variety of ways, (a routine prophylactic intervention, for 
acute exacerbations of breathlessness), and incorporated with the exercise advice and other 
management strategies as part of a complex intervention. The common theme was one of 
reclaiming control with accompanying improvement in quality of life.  
ii) The fan helps reduce their recovery time 
Several participants noted that one of the best aspects of using the fan was that it helped 
reduce their breathlessness recovery time after exertion.  
 
[Insert Text Box 1 here] 
 
© 2017. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/
9 
iii) The trial: a positive experience 
Overall, participants had a very positive experience in the trial, both enjoying the experience 
for themselves, but also the hope that it may help others. Participants also welcomed a study 
investigating breathlessness as a ‘symptom’ rather than as a ‘disease’ as most participants 
experienced focusing on managing the underlying disease, and viewing persistent 
breathlessness as being the inevitable result of smoking.  
 
[Insert Text Box 3 here] 
 
Managing participant expectations and apprehensions: The participants appreciated the 
detailed study explanation and clear study information sheets. While, some participants were 
apprehensive about the physical activity component of the study, they felt reassured by the 
research nurse. 
Getting the equipment right: The participants’ reports of managing the fan and activity 
monitor were mixed. While some appreciated wearing the activity monitor (ActivPAL™), 
and had no problems using it, others experienced some challenges, and some had trouble with 
malfunctioning fans. 
Study assessments: In general, participants found the study assessments acceptable, although 
many felt the COPD Self Efficacy scale was repetitive or irrelevant. 
 
 
DISCUSSION 
It is feasible to conduct a multi-site trial to test the effectiveness of the hand-held fan in this 
patient population in terms of recruitment, completion and acceptability of study measures. 
Despite the challenges of conducting a multi-site feasibility study, this is an important step. 
The team have gained invaluable insights into the elements that need to be refined if such a 
study were to go forward.   
There was a good screen to randomisation ratio in all sites except one where a combination of 
diverse factors impacted on recruitment rates including: a proportion of eligible participants 
having unstable social circumstances, the structure of the ambulatory care respiratory clinics, 
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and a large heart-lung transplant unit that was recruiting similar patients to competing 
studies. The best recruitment rate was seen in a tertiary academic respiratory unit where a 
register of patients willing to be directly contacted about potential studies was used as an 
initial eligibility screen. These patients had chronic non-malignant lung disease and, despite 
having significant breathlessness, were relatively clinically stable. Two sites recruiting 
primarily through palliative care services also achieved good screen-randomisation ratios, 
demonstrating recruitment feasibility in this population. However, attrition due to disease 
deterioration was higher from these sites.  
Participants found most study measures were acceptable with the exception of the COPD 
Self-efficacy Scale.(35) Much has been written about the difficulties of recruiting to 
palliative care trials, and we confirmed the effects of good research-clinical team 
relationships, effective ways of accessing eligible patients, and outcome measure 
burden/relevance.(42-44) In particular, this study showed that although an outcome measure 
might appear ideal and well validated in relevant patient populations, they may not perform 
well in a different context. It was particularly important to test the acceptability of an activity 
monitor before setting out on a definitive trial, and has also allowed simplification of 
measures of activity. We note that all withdrawals occurred in the control arm, and it is 
possible that this attrition may have been partly due to participants’ desire to try the 
intervention or alternatively, as this study could not be blinded, there may have been too little 
potential perceived gain for participants in the comparator arm to continue with the study. 
Implications for the design of a definitive trial 
Value of Information from a definitive trial 
The reason we conduct pilot studies is to evaluate whether or not a subsequent phase III trial 
should be conducted.(45) The need to generate a quality evidence base for new interventions 
is unquestionable. The value proposition, however, of turning this pilot study of the fan as a 
single intervention into an adequately powered phase III study needs to be seriously 
questioned for the following key reasons: 
i.  The intervention has no documented harms, is inexpensive even in resource-
challenged settings, is simple to use, is widely available, does not require a prescription by a 
health professional and, finally, could never be registered as a medical device and the 
qualitative data were clear that participants found the fan helpful.  
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ii. Further, the qualitative data showed that participants incorporated the fan into their 
daily lives in a complex manner. This is consistent with the recently published clinical trials 
(which were not published when this trial was planned) (11;24) whereby the fan forms a 
component of a complex intervention for breathlessness management.  
 
Therefore, research funding investment would be better made in understanding the 
pathophysiological mechanisms involved in perceived relief from the fan. Future clinical 
work could build on the recently published work demonstrating the effectiveness of such a 
complex intervention on mastery over,(11) or distress due to(24) breathlessness. A ‘how to 
use’ guide could be created for improved self-efficacy with freely available, web-based 
instructions for use as part of a complex intervention and to enable incorporation into routine 
clinical management plans. In view of this key consideration, we did not perform sample size 
estimations on the data from this pilot. 
Design: In view of the potential for excess attrition in the control arm, a definitive design 
would allow all participants to receive the complex intervention at some point. Designs such 
as a stepped-wedge trial or wait-list design, would allow this, and it is interesting to note that 
both Farquhar and colleagues and Higginson and colleagues used a wait-list design.(11;24) 
Primary outcome. Taking into account data completion and qualitative data, the primary 
outcome for further work would focus on the symptom of breathlessness, such as “mastery 
over” or “distress due to” or ‘worst breathlessness unpleasantness’. This captures the sense 
that the most important aspect, valued by participants, was the perception that they were able 
to manage the breathlessness better, thus restricting its power to restrict and frighten. None of 
the outcomes measured in this study showed statistically significant change, but it was not 
designed to discard the null hypothesis.  
Secondary outcomes. We would retain the General Self Efficacy score but omit the COPD 
Self Efficacy scale. We would retain an activity monitor as a measure of actual daily step 
activity but omit the 6 MWT which necessitated a clinic visit. In the light of the clearly 
expressed view from participants that the fan reduced recovery time from exertion-induced 
breathlessness, a measure of recovery time from breathlessness induced by simple exercises 
used in the home or clinic setting will be added. Previous feasibility work has shown that 
people with mMRC dyspnea grade 4 breathlessness can complete seated exercise using a 
physiotherapy band to pre-defined levels of intensity.(46) In addition, a striking finding from 
the interviews was that participants perceived that they needed to use their “reliever” inhaler 
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less often in keeping with the fan acting as a strategy to promote self-efficacy and is 
consistent with other studies.(22) If this is confirmed in a definitive trial, this would have 
significant health service cost implications and possibly reduced beta-agonist related 
toxicities. We would therefore add a measure of compliance for this medication.  
Study settings: A mix of respiratory units and palliative care teams would be used, as, 
although the recruitment rate and retention was best in the respiratory unit, recruitment was 
also feasible from palliative care units and provide greater generalizability to study results.  
 
Limitations:  
It was recognized that reporting bias may be introduced by the therapist and outcome 
measurement researcher being the same person and thus rendering any form of blinding 
impossible.  However, as this was a feasibility study and the outcome was to measure the 
variability around response, any bias would be consistent for all arms of the study and it was 
therefore considered difficult to justify single blinding. Other non-pharmacological 
intervention trials for refractory breathlessness have attempted to maintain assessor blinding, 
but found half of the participants broke the blinding through disclosure.(24) 
Strengths of the study: 
The addition of qualitative interviews with a sub-group is a strength of this study, identifying 
that the fan gave overall benefit in managing breathlessness as part of an overall strategy. It 
also highlighting aspects of relief that had not been included in the protocol (recovery from 
exertion induced breathlessness). The overall positive reports are consistent with previous 
qualitative evaluation of breathlessness management programmes where the fan has been 
described as beneficial.(22) 
Generalisability:  
Bearing in mind the feasibility aims of this trial, our findings are applicable for study designs 
in a variety of settings and conditions causing refractory breathlessness.  
 
 
CONCLUSIONS 
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This study confirms the feasibility of a definitive multi-site trial to study the use of the hand-
held fan as part of self-management of chronic refractory breathlessness. It also shows the 
importance of conducting preliminary work to address protocol uncertainties. However, the 
value of information for changing practice or policy is likely to justify the expense of such a 
trial. 
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Table 1. Comparisons of patients’ characteristics at baseline between treatment and 
control groups 
 
 
  
Patients’ Characteristics Treatment 
(n=24) 
Control 
(n=25) 
Age 68.5 (11.6) 67.7 (8.7) 
Male sex 12 (50%) 14 (56%) 
Primary disease 
    COPD 
    Cancer and heart diseases 
    Others     
 
12 (50%) 
6 (254%) 
6 (25%) 
 
11 (46%) 
7 (29%) 
6 (25%) 
MRC Dyspnea Score 3.2 (0.4) 3.4 (0.5) 
NRS 
    Breathlessness average 
    Breathlessness worst 
    Unpleasant average 
    Unpleasant worst  
 
5.7 (1.5) 
7.0 (1.7) 
5.9 (1.9) 
6.9 (1.9) 
 
6.0 (1.6) 
7.6 (1.8) 
6.3 (2.7) 
7.1 (2.6) 
Average steps per day 3838.3 (2171.1) 3601.0 
(2023.2) 
activPALTM (steps) 26064.1 
(16941.2) 
24448.5 
(14119.2) 
6 Minute walk 229.6 (100.0) 215.4 (84.1) 
Life space total score 49.2 (22.0) 51.1 (26.5) 
General Self Efficacy Score 30.2 (5.8) 32.0 (4.4) 
COPD Self Efficacy Score  75.9 (19.6) 64.8 (28.9) 
Median AKPS (IQR) 70 (7.5) 70 (10) 
© 2017. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/
19 
Table 2. Measures for major outcomes at week 4 and comparisons for the differences 
(week 4 minus baseline) between treatment and control groups 
Study 
outcomes  
Treatment 
(n=24) 
Control 
(n=19) 
Treatment 
(n=24) 
Control 
(n=19) 
Results of comparison 
(week 4 minus 
baseline) # 
NRS  
Breathless 
average 
worst 
average 
worst  
 
6.0 (2.0) 
7.0 (3.0) 
5.5 (2.5) 
7.5 (4.5) 
 
5.0 (4.0) 
7.0 (3.0) 
6.0 (5.0) 
48.0 (6.0) 
 
0.0 (3.0) 
0.0 (4.0) 
0.0 (3.0) 
1.0 (4.0) 
 
0.0 (3.0) 
-1.0 (3.0) 
-1.0 (5.0) 
-1.0 (6.0) 
 
p=0.853 
p=0.215 
p=0.426 
p=0.246 
Average 
steps per day 
2840 (3751) 4152 (2909) -167.3 
(1078.0) 
220.0 (674.0) p=0.093 
activPAL™  
 i) steps;  
 
ii) % change) 
 
i) 20063 
(27877) 
 
i) 29064 (20366) 
 
i) -1170.0 
(7606.0); 
ii) -9.6 (12.4)  
 
i) 1538.0  
(5030.0): 
ii) 1.5 (29.3)  
 
p=0.139 
 
p=0.236 
6 Minute 
walk 
234.0 (162.5) 247.5 (110.0) 13.0 (65.0) 3.3 (73.6) p=0.707 
Life space 
total score 
47.8 (28.3) 51.7 (42.0) 0.0 (22.3) 0.7 (31.1) p=0.679 
General Self 
Efficacy 
Score 
29.0 (7.5) 31.5 (8.0) 0.0 (4.5) 0.0 (5.0) p=0.777 
AKPS§  70.0 (20.0) 70.0 (10.0) 0.0 (10.0) 0 (7.5) p=0.816 
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#P-value of Mann-Whitney U test for comparing the median values of the differences between 
treatment and control; §AKPS = Australian-modified Karnofsky Performance Scale; NRS = 
numerical rating scale;  
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Textbox 1: Illustrative Quotes 
The fan as a helpful self-management strategy  
• …Oh it does (help), yeah, yeah. I don’t, I don’t know where I’d have been without that, 
without them fan, the fans, yeah (Participant 36: 77 years, male with heart failure). 
• The first thing when I wake in the morning, I use the fan even though I’m not breathless, so I 
use that as part of my routine…I use it routinely … and then once I get upstairs, I’ll sit in my 
seat at the kitchen table and use the fan again. And within a minute I’ve always settled 
(Participant 40: 73 years male with severe COPD). 
• I might use Ventolin [beta agonist metered dose inhaler (MDI) for relief] as well, but I always 
reach for the fan first… I’m using both… but I would say more the fan … (Participant 49: 77 
years female with COPD).  
• Well I used to use Ventolin up to 30 times a day and I don’t use it at all now…(Participant 40: 
73 year old male with severe COPD).  
• The best things were that it worked, it had a positive effect on my condition. .. now I’ve 
resumed cooking… and other things, I don’t do a lot of – I can’t do gardening or anything like 
that – but I’m more useful than I have been, and I have got no worst effects of the fan, there’s 
only positive about the fan (Participant 40: 73 years, male with severe COPD).  
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Text Box 2: Illustrative Quotes 
The fan helps reduce their recovery time 
 
• Well apart from knowing that after using it for about ten minutes, I know I can put it 
down, get up and get on with what I was doing (Participant 36: 77 years, male with 
Heart Failure);   
• I certainly have been using it (Fan) when I get breathless, and I have a much quicker 
recovery than I used to…(Participant 49: 77 years, female with COPD).  
• If I am somewhere where I haven’t got the fan and I’ve got breathless then it might be 
ten/fifteen minutes before I’ve actually recovered, whereas with the fan it’s usually 
within five minutes recovery. (Participant 27: 55 years, male with Heart Failure). 
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Text box 3: Illustrative Quotes 
The trial: a positive experience 
• Well to this date I don’t really know what COPD means.  I know it’s a problem but 
what’s important to me is the fact that I now become breathless, and this study that I’ve 
been doing on breathlessness it’s been great (Participant 2: 68 years, male with COPD). 
 
• A: Yeah, I was a little bit worried about walking for six minutes… 
Q: Yeah, yeah. And when it came to it, did you feel safe, did you, you, the way it was 
done…?  
A: Yes, yes. Plus I found <research nurse> very good. (Participant 36, 77 years, male 
with heart failure) 
 
• A: The newer doctors seem to be…well they look at my record and say “Ah I see 
you’ve been on prednisolone, try that again...” OK – thank you very much. And I’ve 
given more blood over the years than a blood donor.  
Q: So is your experience very much that when you go, it’s about the disease, the 
condition rather than the breathing and how you cope with that breathing?   
A: Yes. Yes. Yes.  
Q: That brings us nicely on to the study, because one of things we’re trying to do is 
tackle the breathing itself irrespective of what’s causing it.  
A: Yes- that’s why I was keen to do it (Participant 25; 68 years, make with COPD and 
wife) 
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